-
CTN 093: Nevirapine/3TC
An International, Double-blind, Randomized, Phase III Study to Evaluate the Tolerance, Safety and Effectiveness of Nevirapine in Preventing Clinical AIDS Progression Events or Death when Used in Combination with 3TC and Stable (4wks) Background Nucleoside Therapy: Trial results
-
CTN 091: Mixed Carotenoids
A Randomized Clinical Trials of Daily Multivitamin with or without Mixed Carotenoid Supplementation in Advanced HIV Disease: Trial results
-
CTN 090: AZT/3TC/Indinavir (AVANTI II)
A Randomized, Double-blind, Comparative Trial to Evaluate the Efficacy, Safety and Tolerance of Combination Antiretroviral Regimens for the Treatment of HIV-1 Infection: Trial results
-
CTN 089: AZT/3TC/Loviride (AVANTI I)
A Randomized, Double-blind, Comparative Trial to Evaluate the Efficacy, Safety and Tolerance of Combination Antiretroviral Regimens for Treatment of HIV-1 Infection: AZT/3TC vs AZT/3TC/Loviride in Antiretroviral Naïve Patients: Trial results
-
CTN 086: Isoniazid versus Rifabutin
A Phase III Controlled, Double-Blind, Randomized, Multinational Study for the Preventative Therapy of Latent Tuberculosis in HIV-positive Individuals: Isoniazid (300 mg/day x 12 months ) vs. Rifabutin (300 mg/day x 3 months)
-
CTN 083: LiGLA
A Phase I Open-Label Study of the Safety and Potential Efficacy of LiGLA (EF-13) in Advanced HIV Infection
-
CTN 081: 3TC, loviride, AZT
A Randomized, Controlled, Double-Blinded Trial to Compare the Efficacy and Safety of 3TC vs 3TC + Loviride vs Placebo in the Treatment of HIV-1-Infected Persons Taking Concurrent AZT Containing Treatment Regimens with CD4s between 25 and 250: Trial results
-
CTN 080: Hydroxyurea with ddI
A pilot study to assess the potential role of hydroxyurea as an adjuvant therapy among patients with advanced HIV disease receiving didanosine (ddI) therapy
-
CTN 067: Nevirapine, ddI, AZT
A randomized, placebo-controlled, double-blinded, multinational trial comparing the immunologic and virologic effects of nevirapine, ddI and AZT combinations for the treatment of antiretroviral naive HIV+ patients with 200 to 600 T-cells and no AIDS-defining disease: Trial results
-
CTN 057: NAC for TMP-SMX reactions
A Randomized Trial of the Use of N-acetylcysteine for the Prevention of Sulphonamide Hypersensitivity Reactions When Used for the Prevention of Pneumocystis Carinii Pneumonia in Patients with HIV infection: Trial results
-
CTN 047: AZT, ddI, ddC
Combination Therapy for Advanced HIV Disease: A Community-based Randomized Trial of the Safety and Laboratory Effects of ZDV/ddI vs ZDV/ddC
-
CTN 045: BV ara U, acyclovir
Evaluation of SQ32,756 (BV ara U) Versus Acyclovir in the Treatment of Localized Herpes Zoster in HIV Infected Patients
Careers
Interested in joining our team? Here are the current career opportunities with the CTN+ and our collaborators. For Fellowship opportunities, please visit our Postdoctoral Fellowship program page.v
Learn More